Скачать
Overall Survival Update From COLUMBUS Trial in BRAF V600-Mutant Melanoma
Автор: Targeted Oncology
Загружено: 2019-06-04
Просмотров: 747
Описание:
Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, shares updated overall survival data from the phase III COLUMBUS trial examining encorafenib (Braftovi) plus binimetinib (Mektovi) versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
